RBC Capital Defending Biohaven Pharmaceutical Holding (BHVN): 'We Would Be Buyers on Weakness'
Tweet Send to a Friend
RBC Capital analyst Leonid Timashev reiterated an Outperform rating and $59.00 price target on Biohaven Pharmaceutical Holding (NYSE: BHVN).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
